(Alliance News) - Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in patients with breast cancer. Read More
(Alliance News) - AstraZeneca PLC on Thursday said Calquence, when used in combination with obinutuzumab, showed a longer-term survival rate in people with a form of leukaemia. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its Evusheld antibody reduces the risk of serious Covid-19 symptoms or death from the virus in vulnerable sufferers. Read More
(Alliance News) - Equities in London had a buoyant start to the week after a four-day break, with oil majors and miners leading the gainers amid optimism over easing Covid rules in China. Read More
(Alliance News) - Stock prices in London were higher at midday on Monday following the long holiday weekend in the UK, after an easing of virus lockdowns in China, while the pound appreciated ahead of a no-confidence vote in Westminster. Read More
(Alliance News) - AstraZeneca PLC on Saturday said its jointly developed breast cancer drug Enhertu showed improved overall survival in a phase III trial, while its leukaemia treatment Calquence showed a sustained survival benefit in another phase III trial. Read More
(Alliance News) - AstraZeneca PLC on Monday announced its Covid-19 vaccine Vaxzevria has received approval from the EU to be used as a third-dose booster jab. Read More
(Alliance News) - Kingfisher on Monday said first-quarter sales were above pre-pandemic levels but had weakened year-on-year. The owner of the B&Q chain of DIY stores also unveiled a GBP300 million share buyback. Read More
(Alliance News) - Kingfisher on Monday said first-quarter sales were above pre-pandemic levels but had weakened year-on-year. The owner of the B&Q chain of DIY stores also unveiled a GBP300 million share buyback. Read More
(Alliance News) - Europe's blue-chip stock benchmarks were drifting aimlessly at midday on Wednesday, as markets seemed unsure how to react to hot inflation figures in the UK and the eurozone. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday afternoon: Read More
(Alliance News) - AstraZeneca PLC on Tuesday said it signed a license agreement with RQ Biotechnology Ltd to develop, manufacture and sell Covid antibodies worldwide. Read More
(Alliance News) - AstraZeneca PLC on Sunday said its rescue medication candidate PTO27 showed positive results in its Mandala Phase III trial. Read More
(AllianceNews) - NetScientific PLC on Monday said its subsidiary ProAxsis Ltd had successfully completed the development and evaluation of an AstraZeneca PLC Covid-19 antibody test with "impressive" results. Read More
(Alliance News) - AstraZeneca PLC on Thursday reported several positive developments in its pipeline, including its breast cancer drug clearing another regulatory hurdle, and positive phase III trial results for Farxiga and Ultomiris. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its checkpoint inhibitor drug Imfinzi, generically durvalumab, has been granted priority review by the US Food & Drug Administration. Read More
(Alliance News) - JD Wetherspoon on Wednesday said sales improved steadily since the ending of all Covid restrictions, but the pub chain said virus woes have been replaced by "considerable pressure on costs" as a new source of concern. Read More
(Alliance News) - Stocks in London on Friday ended a volatile month of April in a positive fashion, amid a continued rush of company earnings, while markets in the US sank as high-profile tech names disappointed. Read More
(Alliance News) - AstraZeneca PLC on Friday reported a sharp rise in first-quarter revenue, though profit declined, and the drugmaker also announced plans for a new strategic site in the US. Read More
(Alliance News) - Stock prices in London are seen opening higher on Friday, making a confident end to a tricky month for markets, which have faced Covid-19 worries in China, alongside rampant inflation and central bank monetary tightening in response. Read More